Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.

Journal Article (Journal Article;Review)

Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide. In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis. In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months. These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.

Full Text

Duke Authors

Cited Authors

  • Jones, J; Ciombor, K; Wu, C; Bekaii-Saab, T; Strickler, J

Published Date

  • October 21, 2021

Published In

Volume / Issue

  • 35 / 10

Start / End Page

  • 654 - 660

PubMed ID

  • 34677922

International Standard Serial Number (ISSN)

  • 0890-9091

Digital Object Identifier (DOI)

  • 10.46883/ONC.2021.3510.0654


  • eng

Conference Location

  • United States